Manufacturer VerifiedUnited States
Stryker Corporation
Stryker
Stryker Corporation is one of the world's leading medical technology companies, founded in 1941 by Dr. Homer Stryker in Portage, Michigan, United States. Operating through three core divisions — MedSurg and Neurotechnology, Orthopaedics, and Spine — the company designs and manufactures a comprehensive portfolio of surgical equipment, neurotechnology devices, orthopaedic implants, and emergency medical products, encompassing powered surgical instruments, endoscopy visualization systems, patient handling and emergency medical equipment, neurosurgical navigation and cranial devices, joint replacement implants for hip knee and shoulder, trauma fixation systems, and bone cement products. With annual revenue of US$25.1 billion, Stryker operates 40+ manufacturing and R&D facilities worldwide, employing more than 55,000 employees across 75+ countries. The company consistently ranks among the Fortune 500 and has been named one of Fortune's "World's Most Admired Companies" for multiple consecutive years, driven by its relentless acquisition strategy and product innovation pipeline.
Strengths: Dominant market position across MedSurg and Orthopaedics with leading shares in powered surgical instruments, patient handling, and joint replacement. Proven M&A execution with over 60 acquisitions since 2010, consistently integrating targets and extracting synergies. Strong innovation pipeline anchored by the Mako robotic-arm assisted surgery platform with continued indication expansion. Diversified revenue base spanning capital equipment, disposables, and implantables across multiple surgical specialties. Exceptional financial discipline with consistent double-digit adjusted EPS growth and expanding operating margins.
Weaknesses: Heavy acquisition dependence creates integration risks and goodwill exposure, with potential for value-destructive deals in competitive bidding environments. Exposure to hospital capital budget cycles with a significant portion of MedSurg revenue tied to capital equipment purchasing. Pricing pressure from hospital group purchasing organizations and value-based purchasing programs in major markets.Read MoreShow Less
Strengths: Dominant market position across MedSurg and Orthopaedics with leading shares in powered surgical instruments, patient handling, and joint replacement. Proven M&A execution with over 60 acquisitions since 2010, consistently integrating targets and extracting synergies. Strong innovation pipeline anchored by the Mako robotic-arm assisted surgery platform with continued indication expansion. Diversified revenue base spanning capital equipment, disposables, and implantables across multiple surgical specialties. Exceptional financial discipline with consistent double-digit adjusted EPS growth and expanding operating margins.
Weaknesses: Heavy acquisition dependence creates integration risks and goodwill exposure, with potential for value-destructive deals in competitive bidding environments. Exposure to hospital capital budget cycles with a significant portion of MedSurg revenue tied to capital equipment purchasing. Pricing pressure from hospital group purchasing organizations and value-based purchasing programs in major markets.
United StatesFounded 194155,409US$25.1 B40+ manufacturing and R&D… / 100
Listed onNYSESYK
Listed market data
SYK · NYSE · weeklyHistory →- Market cap
- $113 B
- Share price
- USD 294.66
- 1Y change
- -21.3%
- Recent change
- +0.0%
- Since first close
- ×3,317
- Revenue (TTM)
- $25.8 B
10-22 → 10-23
from 1980-03
Revenue FY 2026 · updated 2026-10-23Source ↗
Financial history
Full market historyMonthCloseMarket capChange
- 2026-10USD 294.66$113 B+7.0%
- 2026-09USD 275.39$101 B-15.0%
- 2026-08USD 323.80$119 B-0.6%
- 2026-07USD 325.70$120 B+3.4%
- 2026-06USD 314.84$116 B+3.2%
- 2026-05USD 305.09$112 B-3.2%
- 2026-04USD 315.13$116 B-4.1%
- 2026-03USD 328.59$121 B-15.2%
- 2026-02USD 387.46$143 B+4.8%
- 2026-01USD 369.56$136 B+5.1%
- 2025-12USD 351.47$129 B-5.3%
- 2025-11USD 371.18$137 B—
Monthly closes · 2025-11 – 2026-10 · Full market history
In the press
All coverage →5 latest headlines1- Stryker incident update Monday - KWCHwww.kwch.com2026-10-20
- Driver involved in deadly Stryker crash released from custody - KWCHwww.kwch.com2026-10-19
- Driver released from custody, no charges filed after deadly incident at Stryker Sports Complex - KWCHwww.kwch.com2026-10-18
- Is FDA-Cleared Sonopet 3 Transforming the Investment Case for Stryker’s Surgical Platform Strategy (SYK)?finance.yahoo.com2026-10-15
- What Is Stryker (SYK) Really Getting From Its $400 Million Robotics Deal?finance.yahoo.com2026-10-15
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.
Stryker Corporation is a vertically integrated medical technology manufacturer, controlling every stage from R&D and precision manufacturing to sterile packaging and global distribution. Unlike many medical device peers that rely heavily on contract manufacturing, Stryker maintains over 40 proprietary manufacturing and R&D facilities worldwide, including specialized machining centers for orthopaedic implants, cleanroom assembly for powered surgical tools, and a growing network of Mako robotic system production lines. The company's operating model emphasizes continuous operational improvement and lean manufacturing discipline, enabling it to deliver consistent margin expansion while absorbing the costs of dozens of acquisitions.
MedSurg and Neurotechnology – Surgical Instruments & Patient Handling
• Powered surgical instruments and handpieces for orthopaedic, neuro, and ENT procedures
• Endoscopy visualization systems including 4K and fluorescence imaging platforms
• Patient handling and emergency medical equipment including stretchers, beds, and defibrillators
• Neurosurgical navigation, cranial closure, and craniomaxillofacial implant systems
Orthopaedics and Spine – Joint Replacement & Trauma
• Mako robotic-arm assisted surgery platform for total hip, total knee, and partial knee arthroplasty
• Primary and revision hip and knee implant systems including Triathlon and Insignia
• Shoulder arthroplasty systems for anatomic and reverse total shoulder replacement
• Trauma and extremities fixation systems including plates, screws, and intramedullary nails
• Bone cement, wound management, and orthobiologics products
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $25.1 B | $3.2 B |
| 2024 | $22.6 B | $3 B |
| 2023 | $20.5 B | $3.2 B |
| 2022 | $18.4 B | $2.4 B |
| 2021 | $17.1 B | $2 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Portage, Michigan, United States
Founded
1941
Employees
55,409
Revenue
US$25.1 B (2025)
Market cap
$113 B
Factories
40+ manufacturing and R&D facilities worldwide
Presence
75+ countries
Listing
NYSE: SYKCategories
Related
Similar listed companies
- Nvidia Corporation· $5.2 T
- Eli Lilly and Company· $1.1 T
- Micron Technology, Inc.· $994 B
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: SYK , Data Sources & Methodology
Stryker Official Website
Stryker Corporation - Wikipedia
Stryker Investor Relations
Stryker Revenue - Macrotrends
Stryker - Fortune 500